Dopavision is pioneering the development of digital therapeutics, specifically targeting childhood myopia through its lead product, MyopiaX®, which utilizes selective ocular light stimulation to non-invasively engage the eye's growth regulation mechanisms
Dopavision is pioneering the development of digital therapeutics, specifically targeting childhood myopia through its lead product, MyopiaX®, which utilizes selective ocular light stimulation to non-invasively engage the eye's growth regulation mechanisms.